ethyl 7-fluoro-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 7-fluoro-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate
• 英文别名: ethyl 7-fluoro-1-methyl-4-oxoquinoline-3-carboxylate
• 化学式: C₁₃H₁₂FNO₃
• 分子量: 249.242
• InChiKey: FSHSGWPMKVCLCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-氟-2-甲基苯甲酸 在 碘苯二乙酸 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 、 顺-1,2-二氯乙烯 、 乙醚 、 乙醇 、 甲苯 为溶剂， 反应 31.75h， 生成 ethyl 7-fluoro-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate
  参考文献：
  名称：

  用于喹诺酮支架合成的无金属高价碘促进串联羰基迁移和未活化的 C(Ph)–C(Alkyl) 键断裂

  摘要：

  描述了一种出人意料的碘（III）介导的 3-（甲基氨基）-2-（2-取代苯甲酰基）丙烯酸酯的 C（sp 3）-C（sp 2）键断裂，用于有效合成特权支架 4-喹诺酮类药物。值得注意的是，广泛的烷基（例如甲基、叔丁基或烷基链）可以在该系统中方便地裂解。详细的机制研究表明，转化通过级联同环化和 1,2-羰基迁移进行，较小的键能通过烯胺自由基中间体决定邻位C-C 键断裂而不是 C-H 键断裂。

  DOI：

  10.1039/d2cc02245a

文献信息

• Treatment of gastroparesis in certain patient groups
  申请人：R. T. Alamo Ventures I, LLC

  公开号：US06451813B1

  公开（公告）日：2002-09-17

  Methods for treating specific patient groups for gastroparesis are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives) in patients with symptoms of gastroparesis who are otherwise free of cardiac disease and/or who have not been given organic nitrates.

  本发明的方法包括在症状为胃排空延迟而无心脏疾病或未接受有机硝酸酯的患者中使用含喹诺酮（及其衍生物）的药物组合物，用于治疗特定患者群体的胃排空延迟。
• Methods for the treatment of central nervous system disorders in certain patient groups
  申请人：R.T. Alamo Venturesi, LLC

  公开号：US06458804B1

  公开（公告）日：2002-10-01

  Methods and compositions for treating specific patient groups for Central Nervous System disorders, including but not limited to Tourette Syndrome, are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives thereof) in patients with symptoms of a Central Nervous System Disorder who are otherwise free of cardiac disease and/or who have not been given organic nitrates.

  为治疗特定患者群体的中枢神经系统疾病（包括但不限于抽动症），提供了方法和组合物。本发明的方法包括利用含有喹诺酮（及其衍生物）的药物组合物治疗中枢神经系统疾病症状的患者，这些患者除心脏病和/或未接受有机硝酸酯治疗外。
• Treatment of cardiovascular disease with quinolinone enantiomers
  申请人：R.T. Alamo Ventures I, L.L.C.

  公开号：US20020143031A1

  公开（公告）日：2002-10-03

  The present invention is directed to compositions and methods for treating cardiovascular disease. In a preferred embodiment, the present invention contemplates using the enantiomers of flosequinan (and formulations comprising flosequinan) in subjects not concurrently treated with nitrites or nitrates.

  本发明涉及用于治疗心血管疾病的组合物和方法。在一个优选实施例中，本发明考虑在未同时接受硝酸盐或硝酸酯治疗的受试者中使用氟斯奎南的对映体（以及含有氟斯奎南的配方）。
• 1,4dihydroquinoline-3-carboxamides
  申请人：The Boots Company plc

  公开号：US04855291A1

  公开（公告）日：1989-08-08

  Quinolones of the formula I ##STR1## in which the dotted line between positions 2 and 3 of the quinolone ring represents an optional bond; R is hydrogen or lower alkyl; R.sub.1 is lower alkyl; and R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, are hydrogen, halo, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, trifluoromethyl, cyano, fluorinated lower alkoxy, phenyl optionally substituted by one or two substituents selected from lower alkyl, lower alkoxy, lower alkylthio, halo and trifluoromethyl, the group --OAr or the group --S(O).sub.n Ar in which Ar is phenyl optionally substituted by one or two substituents selected from lower alkyl, lower alkoxy, lower alkylthio, halo and trifluoromethyl and n is 0, 1 or 2, or the group --NR.sub.5 R.sub.6 or the N-oxide thereof in which R.sub.5 and R.sub.6, which may be the same or different, are lower alkyl or, together with the nitrogen atom to which they are attached, form a 5-7 membered ring optionally containing an additional hetero atom selected from oxygen, nitrogen and sulphur have utility as antihypertensive agents. Novel quinolones are those of the above-defined formula I, provided that (a) when the optional 2,3-bond is present R.sub.1 is methyl and R is hydrogen, at least one of R.sub.2, R.sub.3 and R.sub.4 is other than hydrogen and (b) when the optional 2,3-bond is present, R is lower alkyl and R.sub.3 and R.sub.4 are hydrogen, R.sub.2 is other than hydrogen or lower alkoxy. Pharmaceutical compositions comprising a novel quinolone of the above formula I together with a pharmaceutically acceptable carrier are described and claimed. Processes for preparing the novel quinolones are also described.

  式I中的喹诺酮化合物为：##STR1## 其中喹诺环的2和3位之间的虚线表示可选键；R为氢或低碳基；R.sub.1为低碳基；R.sub.2、R.sub.3和R.sub.4可相同可不同，为氢、卤素、低碳基、低氧基、低硫基、低硫酰基、低硫酸基、三氟甲基、氰基、氟化低氧基、苯基（可选用一个或两个来自低碳基、低氧基、低硫基、卤素和三氟甲基的取代基）、--OAr或--S（O）.sub.nAr（其中Ar为苯基，可选用一个或两个来自低碳基、低氧基、低硫基、卤素和三氟甲基的取代基，n为0、1或2）或--NR.sub.5R.sub.6或其N-氧化物，其中R.sub.5和R.sub.6可相同可不同，为低碳基或与它们所连接的氮原子一起形成一个5-7成员环，该环可选包含一个来自氧、氮和硫的额外杂原子。该类化合物具有降压作用。新型喹诺酮化合物的定义如下：在可选的2,3-键存在时，R.sub.1为甲基且R为氢，R.sub.2、R.sub.3和R.sub.4中至少有一个不为氢；在可选的2,3-键存在时，R为低碳基，R.sub.3和R.sub.4为氢，R.sub.2不为氢或低氧基。本文还描述了含有上述式I中新型喹诺酮化合物和药学上可接受的载体的制药组合物，并对制备新型喹诺酮化合物的过程进行了描述。
• TREATMENT OF GASTROPARESIS IN CERTAIN PATIENT GROUPS
  申请人：R.T. Alamo Ventures I, L.L.C,

  公开号：US20020143030A1

  公开（公告）日：2002-10-03

  Methods for treating specific patient groups for gastroparesis are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives) in patients with symptoms of gastroparesis who are otherwise free of cardiac disease and/or who have not been given organic nitrates.

  本发明提供了用于治疗特定患者群体的胃排空障碍的方法。本发明的方法包括在没有心脏疾病和/或未被给予有机硝酸酯的胃排空障碍症状患者中利用含有喹啉酮（和衍生物）的药物组合物。